vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Richmond Mutual Bancorporation, Inc. (RMBI). Click either name above to swap in a different company.
Richmond Mutual Bancorporation, Inc. is the larger business by last-quarter revenue ($13.1M vs $9.1M, roughly 1.4× Protalix BioTherapeutics, Inc.). Richmond Mutual Bancorporation, Inc. runs the higher net margin — 26.1% vs -60.3%, a 86.5% gap on every dollar of revenue. On growth, Richmond Mutual Bancorporation, Inc. posted the faster year-over-year revenue change (18.1% vs -49.9%). Richmond Mutual Bancorporation, Inc. produced more free cash flow last quarter ($14.6M vs $1.6M). Over the past eight quarters, Richmond Mutual Bancorporation, Inc.'s revenue compounded faster (9.1% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Richmond Mutual Bancorporation, Inc. is a U.S.-based bank holding company operating primarily in Indiana. It offers a full range of personal and commercial banking solutions including deposit accounts, mortgage loans, small business lending, and wealth management services, serving local retail consumers and small-to-medium enterprise clients via its regional branch network.
PLX vs RMBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $13.1M |
| Net Profit | $-5.5M | $3.4M |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | — |
| Net Margin | -60.3% | 26.1% |
| Revenue YoY | -49.9% | 18.1% |
| Net Profit YoY | -184.8% | 37.7% |
| EPS (diluted) | $-0.06 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $13.1M | ||
| Q3 25 | $17.9M | $12.6M | ||
| Q2 25 | $15.7M | $11.8M | ||
| Q1 25 | $10.1M | $11.4M | ||
| Q4 24 | $18.2M | $11.1M | ||
| Q3 24 | $18.0M | $10.8M | ||
| Q2 24 | $13.5M | $10.7M | ||
| Q1 24 | — | $11.0M |
| Q4 25 | $-5.5M | $3.4M | ||
| Q3 25 | $2.4M | $3.6M | ||
| Q2 25 | $164.0K | $2.6M | ||
| Q1 25 | $-3.6M | $2.0M | ||
| Q4 24 | $6.5M | $2.5M | ||
| Q3 24 | $3.2M | $2.5M | ||
| Q2 24 | $-2.2M | $2.1M | ||
| Q1 24 | — | $2.4M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | -41.0% | — | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -18.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | -60.3% | 26.1% | ||
| Q3 25 | 13.2% | 28.6% | ||
| Q2 25 | 1.0% | 22.0% | ||
| Q1 25 | -35.8% | 17.2% | ||
| Q4 24 | 35.6% | 22.4% | ||
| Q3 24 | 18.0% | 23.0% | ||
| Q2 24 | -16.4% | 19.3% | ||
| Q1 24 | — | 21.6% |
| Q4 25 | $-0.06 | $0.35 | ||
| Q3 25 | $0.03 | $0.36 | ||
| Q2 25 | $0.00 | $0.26 | ||
| Q1 25 | $-0.05 | $0.20 | ||
| Q4 24 | $0.10 | $0.25 | ||
| Q3 24 | $0.03 | $0.24 | ||
| Q2 24 | $-0.03 | $0.20 | ||
| Q1 24 | — | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $33.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $145.8M |
| Total Assets | $82.3M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $33.1M | ||
| Q3 25 | $13.6M | $34.3M | ||
| Q2 25 | $17.9M | $27.2M | ||
| Q1 25 | $19.5M | $27.0M | ||
| Q4 24 | $19.8M | $21.8M | ||
| Q3 24 | $27.4M | $19.6M | ||
| Q2 24 | $23.4M | $19.0M | ||
| Q1 24 | — | $20.3M |
| Q4 25 | $48.2M | $145.8M | ||
| Q3 25 | $52.9M | $140.0M | ||
| Q2 25 | $49.9M | $132.3M | ||
| Q1 25 | $45.2M | $130.9M | ||
| Q4 24 | $43.2M | $132.9M | ||
| Q3 24 | $32.4M | $140.0M | ||
| Q2 24 | $28.6M | $131.1M | ||
| Q1 24 | — | $132.4M |
| Q4 25 | $82.3M | $1.5B | ||
| Q3 25 | $82.3M | $1.5B | ||
| Q2 25 | $78.5M | $1.5B | ||
| Q1 25 | $73.9M | $1.5B | ||
| Q4 24 | $73.4M | $1.5B | ||
| Q3 24 | $61.6M | $1.5B | ||
| Q2 24 | $91.5M | $1.5B | ||
| Q1 24 | — | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $16.0M |
| Free Cash FlowOCF − Capex | $1.6M | $14.6M |
| FCF MarginFCF / Revenue | 17.8% | 111.9% |
| Capex IntensityCapex / Revenue | 4.4% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 4.68× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $26.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $16.0M | ||
| Q3 25 | $-3.7M | $6.3M | ||
| Q2 25 | $-5.2M | $4.8M | ||
| Q1 25 | $-5.1M | $2.2M | ||
| Q4 24 | $4.0M | $14.8M | ||
| Q3 24 | $4.1M | $2.9M | ||
| Q2 24 | $-3.6M | $2.9M | ||
| Q1 24 | — | $2.2M |
| Q4 25 | $1.6M | $14.6M | ||
| Q3 25 | $-4.2M | $5.8M | ||
| Q2 25 | $-5.7M | $4.2M | ||
| Q1 25 | $-5.4M | $2.1M | ||
| Q4 24 | $3.6M | $14.3M | ||
| Q3 24 | $4.0M | $2.8M | ||
| Q2 24 | $-3.8M | $2.8M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | 17.8% | 111.9% | ||
| Q3 25 | -23.7% | 46.2% | ||
| Q2 25 | -36.2% | 35.6% | ||
| Q1 25 | -53.0% | 18.4% | ||
| Q4 24 | 19.6% | 129.3% | ||
| Q3 24 | 22.4% | 25.7% | ||
| Q2 24 | -28.1% | 26.2% | ||
| Q1 24 | — | 18.7% |
| Q4 25 | 4.4% | 10.4% | ||
| Q3 25 | 2.8% | 3.7% | ||
| Q2 25 | 2.8% | 5.3% | ||
| Q1 25 | 3.0% | 0.7% | ||
| Q4 24 | 2.3% | 4.2% | ||
| Q3 24 | 0.5% | 1.1% | ||
| Q2 24 | 1.3% | 1.1% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | — | 4.68× | ||
| Q3 25 | -1.58× | 1.75× | ||
| Q2 25 | -31.91× | 1.86× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | 0.61× | 5.96× | ||
| Q3 24 | 1.27× | 1.17× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | — | 0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
RMBI
Segment breakdown not available.
